Mercer Global Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Mercer Global Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$146K	Buy	+10,172	New	+$113K	﹤0.01%	3526

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Mercer Global Advisors's ZVRA Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 10,172 shares worth $146K. The stake represents ﹤0.01% of the portfolio and ranks #3526 among its holdings.

144 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Mercer Global Advisors held 10,172 shares of Zevra Therapeutics worth $146K as of Q2 2026.
Zevra Therapeutics was a new Mercer Global Advisors position in Q2 2026.
Zevra Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3526 holding.
144 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.